Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2012 Sep 14:7:157.
doi: 10.1186/1748-717X-7-157.

Multimodal hypoxia imaging and intensity modulated radiation therapy for unresectable non-small-cell lung cancer: the HIL trial

Vasileios Askoxylakis  1 , Julien Dinkel, Monika Eichinger, Bram Stieltjes, Gregor Sommer, Ludwig G Strauss, Antonia Dimitrakopoulou-Strauss, Annette Kopp-Schneider, Uwe Haberkorn, Peter E Huber, Marc Bischof, Jürgen Debus, Christian Thieke
Affiliations
Clinical Trial

Multimodal hypoxia imaging and intensity modulated radiation therapy for unresectable non-small-cell lung cancer: the HIL trial

Vasileios Askoxylakis et al. Radiat Oncol. .

Abstract

Background: Radiotherapy, preferably combined with chemotherapy, is the treatment standard for locally advanced, unresectable non-small cell lung cancer (NSCLC). The tumor response to different therapy protocols is variable, with hypoxia known to be a major factor that negatively influences treatment effectiveness. Visualisation of tumor hypoxia prior to the use of modern radiation therapy strategies, such as intensity modulated radiation therapy (IMRT), might allow optimized dose applications to the target volume, leading to improvement of therapy outcome. (18)F-fluoromisonidazole dynamic positron emission tomography and computed tomography ((18) F-FMISO dPET-CT) and functional magnetic resonance imaging (functional MRI) are attractive options for imaging tumor hypoxia.

Methods/design: The HIL trial is a single centre study combining multimodal hypoxia imaging with (18) F-FMISO dPET-CT and functional MRI, with intensity modulated radiation therapy (IMRT) in patients with inoperable stage III NSCLC. 15 patients will be recruited in the study. All patients undergo initial FDG PET-CT and serial (18) F-FMISO dPET-CT and functional MRI before treatment, at week 5 of radiotherapy and 6 weeks post treatment. Radiation therapy is performed as inversely planned IMRT based on 4D-CT.

Discussion: Primary objectives of the trial are to characterize the correlation of (18) F-FMISO dPET-CT and functional MRI for tumor hypoxia imaging in NSCLC and evaluate possible effects of radiation therapy on tumor re-oxygenation. Further objectives include the generation of data regarding the prognostic value of (18) F-FMISO dPET-CT and functional MRI for locoregional control, progression free survival and overall survival of NSCLC treated with IMRT, which will form the basis for larger clinical trials focusing on possible interactions between tumor oxygenation and radiotherapy outcome.

Trial registration: The ClinicalTrials.gov protocol ID is NCT01617980.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Trial workflow.
See this image and copyright information in PMC

References

    1. Askoxylakis V, Thieke C, Pleger ST, Most P, Tanner J, Lindel K, Katus HA, Debus J, Bischof M. Long-term survival of cancer patients compared to heart failure and stroke: a systematic review. BMC Cancer. 2010;10:105. doi: 10.1186/1471-2407-10-105. - DOI - PMC - PubMed
    1. Willner J, Baier K, Caragiani E, Tschammler A, Flentje M. Dose, volume, and tumor control prediction in primary radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002;52:382–389. doi: 10.1016/S0360-3016(01)01823-5. - DOI - PubMed
    1. Anderson CS, Curran WJ. Combined modality therapy for stage III non-small-cell lung cancer. Semin Radiat Oncol. 2010;20:186–191. doi: 10.1016/j.semradonc.2010.01.007. - DOI - PubMed
    1. Lee CB, Stinchcombe TE, Moore DT, Morris DE, Hayes DN, Halle J, Rosenman JG, Rivera MP, Socinski MA. Late complications of high dose (>/=66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancer. J Thorac Oncol. 2009;4:74–79. doi: 10.1097/JTO.0b013e3181915028. - DOI - PubMed
    1. Christian JA, Bedford JL, Webb S, Brada M. Comparison of inverse-planned three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2007;67:735–741. doi: 10.1016/j.ijrobp.2006.09.047. - DOI - PubMed

Publication types

MeSH terms

Associated data